

Special Issue

Bluetongue, Epizootic Haemorrhagic Disease, and Other Emerging Orbiviruses, 2nd Edition

Message from the Guest Editor

The recent emergence of Bluetongue virus serotype 3 (BTV-3) in Europe and the expanding distribution of Epizootic Haemorrhagic Disease virus (EHDV) highlight the ongoing challenges posed by emerging orbiviruses worldwide. These vector-borne pathogens continue to threaten livestock and wildlife, with potentially severe economic and ecological consequences. This special issue aims to gather cutting-edge research focused on various aspects of orbivirus biology, including molecular characterization, epidemiology, pathogenesis, diagnostic advancements, vaccination strategies, and disease control. Studies addressing novel orbiviruses, their ecological and evolutionary dynamics, as well as innovative approaches to surveillance and outbreak response, are particularly welcome. By providing an updated and comprehensive overview of orbivirus research, this issue seeks to contribute to the development of effective control and prevention measures.

Guest Editor

Dr. Ludovic Martinelle

CARE-FEPEX Experimental Station, Fundamental and Applied Research for Animals & Health (FARAH) Center, Faculty of Veterinary Medicine, University of Liege, 4000 Liege, Belgium

Deadline for manuscript submissions

31 January 2026



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/236461

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,
National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).